



## Supplementary Material




**Figure S1.** Extracellular vesicles (EVs) from the tissues of patients with pancreatic cancer. Size distribution of EVs obtained from tissues. The average size was  $63.42 \pm 19.02$  nm.




**Figure S2.** Beta diversity of tissue EV-derived microbiomes in tumor and normal tissues in 2-dimension ( $n = 15$ ). (A) Phylum, (B) class, (C) order, (D) family, and (E) genus levels.


(A)




(B)




(C)




(D)




**Figure S3.** Beta diversity of tissue EV-derived microbiomes in tumor and normal tissues in 3-dimension ( $n = 15$ ). (A) Phylum, (B) class, (C) order, (D) family levels.




**Figure S4.** Phylogenetic profiles of EV-derived microbiomes. Common microbiota in paired normal and tumor tissues at the **(A)** phylum, **(B)** class, **(C)** order, and **(D)** family levels.




**Figure S5.** Microbiome composition profiling in the tissues of patients with pancreatic cancer. Clustering of common microbiota in paired normal and tumor tissues ( $n = 15$ ).




**Figure S6.** The abundance of known important microbiotas in human gut between normal and tumor tissues ( $n=15$ ).




**Figure S7.** Abundance of *Tepidimonas* by surgical procedures in tumor tissues (PD; pancreaticoduodenectomy, TPS; total pancreatectomy with splenectomy, DPS; distal pancreatectomy with splenectomy,  $n = 15$ , mean  $\pm$  SEM).




**Figure S8.** Proliferation of cancer cells in the presence of the supernatant of TF in Capan2 and SNU213 ( $n = 5$ , mean  $\pm$  SD, \*  $p < 0.05$ , \*\*\*  $p < 0.001$  ).




**Figure S9.** Proliferation of cancer cells in the presence of the culture medium of *Tepidimonas fonticaldi* in Panc 10.05 and CFPAC-1 cell ( $n = 5$ , mean  $\pm$  SD).




**Figure S10.** Proliferation of cancer cells in the presence of the supernatant of *Tepidimonas fonticaldi* and Gemcitabine in SW1990 and CFPAC-1 cell ( $n = 5$ , mean  $\pm$  SD, \*  $p < 0.05$ ).



**Figure S11.** Alterations in protein of SNAIL with the presence of the supernatant of *Tepidimonas fonticaldi* in HPAF-II and Panc 10.05 cell (1% FBS).



**Figure S12.** Regulation of transcription factors associated epithelial to mesenchymal transition (EMT) by *Tepidimonas fonticaldi* in Panc 10.05 cell (10% FBS,  $n = 4$ , \*\*\* $p < 0.001$ ).



**Figure S13.** Alterations in cancer metabolites in SW1990 cells in the presence of the supernatant of *Tepidimonas fonticaldi* (TF). Metabolic assay was performed in (A) 10% FBS and (B) 1% FBS.

**Table S1.** Clinicopathological information of enrolled patients. WBC; white blood cell, Hb; hemoglobin, Plt; platelet, AST; aspartate aminotransferase, ALT; alanine aminotransferase, ALP; alkaline phosphatase, TP; total protein, Alb; albumin, TB; total bilirubin, BUN; blood urea nitrogen, Crea; creatinine, CA 19-9; carbohydrate antigen 19-9, CEA; carcinoembryonic antigen, DPS; distal pancreatectomy with splenectomy, TPS; total pancreatectomy with splenectomy, PD; pancreaticoduodenectomy, LN; lymph node, n.i.; not identified.

I D	A ge (y )	Sex	WB C (*10 <sup>3</sup> /uL)	Neutro phil (%)			Lymph ocyte (%)			Mon ocyte (%)			Hb (g/ dL)	Plt (*10 <sup>3</sup> /uL)	AS			AL			AL			TP (g/ dL)	Al b (g/ dL)			TB (mg /dL)			BU N (mg /dL)			Cre a (mg /dL)		
				Neutro phil (%)	Lymph ocyte (%)	Mon ocyte (%)	Neutro phil (%)	Lymph ocyte (%)	Mon ocyte (%)	T (I U/ L)	T (I U/ L)	T (I U/ L)			T (I U/ L)	T (I U/ L)	T (I U/ L)	P (I U/ L)	T (I U/ L)	T (I U/ L)	P (I U/ L)	T (I U/ L)	T (I U/ L)	P (I U/ L)	T (I U/ L)	T (I U/ L)	P (I U/ L)	T (I U/ L)	T (I U/ L)	P (I U/ L)						
1	52	Male	7.0	49.8	39.5	6.8	12.8	193	20	21	11.8	6.1	3.7	0.7	9	0.77																				
2	68	Male	9.1	67.1	24.6	7	14.6	180	25	19	12.7	6.4	4	0.7	16	0.76																				
3	64	Male	4.7	71.2	21.8	5.5	13	162	23	12	56	6.7	4.2	0.8	11	0.81																				
4	60	Male	6.5	45.8	45.6	4.9	14	179	20	22	62	6.8	4.3	1.6	11	0.71																				
5	69	Female	5.9	61.4	30.1	7.8	14.6	194	21	17	12.1	6.7	4.1	0.4	10	0.48																				
6	57	Male	6.5	60.5	32	5.6	15.2	264	33	36	91	7.5	4.3	0.9	13	0.98																				
7	74	Male	8.8	61.1	25.9	11.8	11.8	216	49	74	17.4	6.1	2.8	7.1	13.6	0.95																				
8	52	Male	9.1	58.1	31.5	7.7	14.9	268	26	21	93	7.5	4.6	0.7	14	1.06																				
9	61	Male	7.6	60.5	29.1	5.6	13.4	216	30	52	76	6.9	4.3	0.4	10	0.74																				
10	79	Male	5.6	40.9	44.5	7.4	13.5	217	43	55	21.1	5.7	3.4	1.4	10	0.71																				
11	71	Male	8.4	59.2	31.3	7.6	13.7	183	22	29	38	6.6	3.6	0.5	10	0.72																				
12	73	Female	4.5	56.1	35	6.9	12.1	224	33	22	13.0	6.5	3.6	0.2	12	0.77																				
13	66	Female	6.0	57.2	31.3	7.5	13.3	258	21	15	58	6.4	3.6	0.3	18	0.7																				

1 4	71	Female	2.1	32.3	58	2.4	11. 7	261	21	11	52	6.4	3.3	0.2	19	0.73
1 5	58	Male	6.0	52.6	37.5	5.7	15. 7	144	22	25	10 3	7.1	3.9	0.4	15	0.89

**Table S1.** (Continued). Clinicopathological information of enrolled patients. WBC; white blood cell, Hb; hemoglobin, Plt; platelet, AST; aspartate aminotransferase, ALT; alanine aminotransferase, ALP; alkaline phosphatase, TP; total protein, Alb; albumin, TB; total bilirubin, BUN; blood urea nitrogen, Crea; creatinine, CA 19-9; carbohydrate antigen 19-9, CEA; carcinoembryonic antigen, DPS; distal pancreatectomy with splenectomy, TPS; total pancreatectomy with splenectomy, PD; pancreaticoduodenectomy, LN; lymph node, n.i.; not identified.

ID	CA19-9 (U/mL)	CEA (ng/mL)	Operation type	Tumor or location	Tumor Size (cm)	Tumor differentiation	Lymphovascular Invasion	Perineural Invasion	Metastatic LN	No. of metastatic LN	Neoadjuvant chemotherapy	Recurrence within 4 y
1	8.5	2	TPS	head	9.2	mod	present	present	present	4	none	present
2	1290	2.1	DPS	body	3.1	mod	absent	present	present	10	none	absent
3	393	1.7	DPS	body	5.1	mod	absent	present	present	1	none	present
4	22	2.6	DPS	tail	2.2	mod	absent	present	absent	0	none	absent
5	17.7	3	DPS	body	4.0	mod	absent	present	absent	0	none	present
6	254	2.9	DPS	body	2.6	wel	present	present	present	6	none	present
7	3.4	2.6	PD	head	3.0	mod	absent	present	present	4	none	present
8	9.7	1.3	PD	neck	3.0	mod	absent	present	present	4	none	present
9	57.9	5.5	DPS	body	3.2	mod	absent	present	present	3	none	present
10	244.9	1.8	PD	head	1.8	2	present	present	present	6	none	n.i
11	428.9	1.7	DPS	tail	1.4	mod	present	present	present	2	none	absent
12	18.4	1.2	TPS	head	3.1	mod	absent	present	absent	0	recieved	absent
13	11.2	0.88	DPS	body	1.7	mod	absent	absent	absent	0	none	absent
14	40.4	1.6	DPS	tail	3.5	mod	present	present	present	2	none	present
15	53.9	1.9	DPS	body	2.4	mod	absent	present	absent	0	none	absent

**Table S2.** Comparative analysis of taxa between normal and tumor tissues.

Taxon	Normal Tissue		Tumor Tissue		t test p-value
	Mean	SD	Mean	SD	
Bacteria;p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Bacteroidaceae;g_Bacteroides	0.06	0.06	0.08	0.0	0.232
	6	4	1	68	
Bacteria;p_Bacteroidetes;c_Flavobacterii;o_Flavobacteriales;f_[Weeksellacea]e;g_Chryseobacterium	0.08	0.15	0.06	0.1	0.440
	8	6	5	24	
Bacteria;p_Proteobacteria;c_Gammaproteobacteria;o_Enterobacteriales;f_Enterobacteriaceae;g_	0.06	0.09	0.05	0.0	0.808
	5	4	9	69	
Bacteria;p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_	0.04	0.03	0.05	0.0	0.258
	1	5	6	52	
Bacteria;p_Proteobacteria;c_Betaproteobacteria;o_Burkholderiales;f_Comamonadaceae;g_	0.06	0.10	0.05	0.0	0.806
	0	9	5	90	
Bacteria;p_Proteobacteria;c_Gammaproteobacteria;o_Pseudomonadales;f_Moraxellaceae;g_Acinetobacter	0.07	0.13	0.04	0.0	0.223
	7	4	7	80	
Bacteria;p_Proteobacteria;c_Gammaproteobacteria;o_Pseudomonadales;f_Pseudomonadaceae;g_Pseudomonas	0.02	0.02	0.03	0.0	0.375
	9	8	7	34	
Bacteria;p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Faecalibacterium	0.02	0.02	0.03	0.0	0.307
	4	4	1	28	
Bacteria;p_Firmicutes;c_Bacilli;o_Lactobacillales;f_Streptococcaceae;g_Streptococcus	0.02	0.02	0.03	0.0	0.215
	3	3	0	22	
Bacteria;p_Proteobacteria;c_Betaproteobacteria;o_Burkholderiales;f_Comamonadaceae;g_Comamonas	0.02	0.04	0.02	0.0	0.519
	8	1	4	35	
Bacteria;p_Actinobacteria;c_Actinobacteria;o_Bifidobacteriales;f_Bifidobacteriaceae;g_Bifidobacterium	0.02	0.02	0.02	0.0	0.744
	6	3	4	22	
Bacteria;p_Verrucomicrobia;c_Verrucomicrobiae;o_Verrucomicrobiales;f_Verrucomicrobiaceae;g_Akkermansia	0.01	0.01	0.02	0.0	0.077
	5	7	4	18	
Bacteria;p_Proteobacteria;c_Gammaproteobacteria;o_Enterobacteriales;f_Enterobacteriaceae;g_Citrobacter	0.01	0.02	0.02	0.0	0.325
	4	6	1	25	
Unassigned;Other;Other;Other;Other;Other	0.01	0.01	0.02	0.0	0.682
	8	4	0	21	
Bacteria;p_Firmicutes;c_Clostridia;o_Clostridiales;f_	0.02	0.02	0.02	0.0	0.561
	5	8	0	19	
Bacteria;p_Proteobacteria;c_Gammaproteobacteria;o_Enterobacteriales;f_Enterobacteriaceae;Other	0.01	0.02	0.02	0.0	0.631
	6	6	0	27	
Bacteria;p_Firmicutes;c_Clostridia;o_Clostridiales;f_Veillonellaceae;g_Dialister	0.00	0.01	0.01	0.0	0.115
	8	0	9	25	
Bacteria;p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;g_	0.01	0.01	0.01	0.0	0.746
	6	7	8	14	
Bacteria;p_Bacteroidetes;c_Flavobacterii;o_Flavobacteriales;f_[Weeksellacea]e;g_Cloacibacterium	0.02	0.04	0.01	0.0	0.278
	5	8	6	25	
Bacteria;p_Bacteroidetes;c_Flavobacterii;o_Flavobacteriales;f_Flavobacteriacae;g_Flavobacterium	0.01	0.03	0.01	0.0	0.392
	0	1	6	51	
Bacteria;p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Prevotellaceae;g_Prevotella	0.01	0.01	0.01	0.0	0.303
	9	8	5	16	
Bacteria;p_Proteobacteria;c_Betaproteobacteria;o_Rhodocyclales;f_Rhodocylaceae;g_	0.01	0.03	0.01	0.0	0.625
	4	5	2	29	
Bacteria;p_Proteobacteria;c_Betaproteobacteria;o_Burkholderiales;f_Comamonadaceae;g_Tepidimonas	0.00	0.00	0.01	0.0	0.035
	4	4	1	13	
Bacteria;p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae;g_Ruminococcus	0.00	0.00	0.01	0.0	0.231
	5	9	0	11	
Bacteria;p_Fusobacteria;c_Fusobacterii;o_Fusobacteriales;f_Fusobacteriaceae;g_Fusobacterium	0.02	0.07	0.00	0.0	0.371
	5	2	9	15	

**Table S3.** PCR primers. ZEB1; zinc finger E-box-binding homeobox 1.

Gene		Sequence (5'→3')	Annealing temperature (°C)	RT-PCR product length (bp)
18s	Forward	CGGCTACCACATCCAAGGAA	60	187
	Reverse	GCTGGAATTACCGCGGCT		
E-cadherin	Forward	TTGCACCGGTCGACAAAGGAC	63	231
	Reverse	TGGATTCCAGAAACGGAGGCC		
ZEB1	Forward	TGCACTGAGTGTGGAAAAGC	58	237
	Reverse	TGGTGATGCTGAAAGAGACG		
Snail	Forward	GGCTCCTTCGTCCTTCTCCT	60	124
	Reverse	CTGGAGATCCTTGGCCTCAG		
Twist	Forward	TGCGGAAGATCATCCCCACG	63	137
	Reverse	GCTGCAGCTTGCATCTTGGA		